
|Videos|April 17, 2017
Neoadjuvant Treatment Strategies for HER2-Positive Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5
































